Publications by authors named "P R Ost"
Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong ADT-free survival or progression-free survival (PFS) in patients with metachronous oligometastatic prostate cancer (omCSPC) patients. While most omCSPC patients have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating PSMA-positive extracellular vesicles (PSMA+EV) and prostate specific antigen (PSA) in a biomarker correlative study using blood samples from three independent patient cohorts.
View Article and Find Full Text PDFArticle Synopsis
- - There is a need for better tools to help manage oligometastatic castration-sensitive prostate cancer (omCSPC), as highlighted in a retrospective study examining the effectiveness of the ArteraAI Prostate Test.
- - This study involved 222 men and measured outcomes like overall survival (OS) and time until the cancer becomes castration-resistant, finding a high MMAI score linked to worse OS and shorter time to resistance.
- - Additionally, the study indicated that patients with high MMAI scores who received metastasis-directed therapy (MDT) had improved metastasis-free survival compared to those with low scores, pointing to the potential of the MMAI biomarker for guiding treatment decisions.
Article Synopsis
- Innovations in advanced prostate cancer have improved outcomes, but there's still a lack of high-level evidence in clinical management, prompting the 2024 Advanced Prostate Cancer Consensus Conference to survey experts for insights.
- A panel of 120 international experts developed and voted on 183 consensus questions through a web-based survey prior to the conference, defining consensus as ≥75% agreement.
- The voting results highlight areas of agreement and disagreement that can guide clinical decisions and future research, with a focus on individualizing treatment based on patient characteristics and encouraging participation in clinical trials.